Anti-doping labs can detect a wide range of banned peptides — from growth hormone releasers to EPO — but routine testing still lags behind research capabilities.
15+ peptide classes detectableAnti-doping labs can identify peptides ranging from small GHRPs to large proteins like EPO, though routine testing capabilities lag behind research methods
What the researchers found
Anti-doping laboratories have developed multiple analytical methods to detect a wide range of peptide drugs in athlete samples. These include chromatographic-mass spectrometric, electrophoretic, immunological, and combined approaches capable of identifying peptides across all molecular sizes.
Low-molecular-weight peptides detected include growth hormone-releasing peptides (GHRPs), ARA-290, TB-500, AOD-9604, CJC-1295, desmopressin, LH-releasing hormones, and synacthen. Intermediate-sized peptides include insulins, IGF-1 and analogs, mechano growth factor, growth hormone, hCG, and erythropoietin. Larger peptides like stamulumab can also be detected.
However, a significant gap remained between what was technically possible in research settings and what could be reliably implemented in routine daily testing of athlete samples.
Why it matters
Peptide doping represents one of the most challenging detection problems in sports drug testing. Unlike traditional small-molecule drugs, peptides are present at extremely low concentrations, are rapidly degraded in the body, and often closely resemble natural human proteins. This review catalogues the state of detection science as of 2014, revealing both the impressive range of peptides that anti-doping labs could identify and the practical limitations preventing comprehensive routine testing.
The numbers in context
Blood, serum, and urine tested · Lower MW peptides: GHRPs, TB-500, AOD-9604, CJC-1295 · Mid MW: insulins, IGF-1, GH, EPO · Higher MW: stamulumab
How the study worked
This is an expert review published in Expert Review of Proteomics that surveys the analytical methods used by anti-doping laboratories to detect peptidic drugs. It covers chromatographic-mass spectrometric techniques, electrophoretic methods, immunological assays, and combined approaches, categorizing detectable peptides by molecular weight.
Who was studied
Review of anti-doping detection methods (no patient/athlete population studied directly)
What this study cannot tell us
As a 2014 review, the detection landscape has evolved significantly with newer mass spectrometry techniques and expanded WADA prohibited lists. The review acknowledges a gap between research-grade detection capability and routine laboratory practice. It does not quantify false positive/negative rates for specific assays.
How to read the evidence
This is a moderate-grade expert review that comprehensively surveys detection methods without conducting new experimental work. It reflects the expert consensus of leading anti-doping analytical chemists.
When this study was published
Published in 2014, detection technology and WADA's prohibited list have both expanded significantly since this review. However, the fundamental analytical challenges and many of the peptides discussed remain relevant.
The bigger picture
This review captures a critical period in anti-doping science when peptide use among athletes was rapidly expanding while detection methods were still catching up. Many of the peptides mentioned — TB-500, CJC-1295, AOD-9604, GHRPs — remain popular in underground sports doping and grey-market peptide sales. Since 2014, WADA has expanded its prohibited list and detection methods have improved, but the fundamental challenge of detecting rapidly-degraded, low-concentration peptides in biological samples persists.
Questions still open
- Has the gap between research-grade and routine anti-doping peptide detection been closed since 2014?
- How do athletes evade detection given the known capabilities of anti-doping labs?
- Are newer peptide drugs being developed faster than detection methods can keep up?
Common questions
Which peptide drugs can anti-doping labs actually detect?
Why is detecting peptide doping harder than detecting steroid doping?
Read the original research
Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.
Expert review of proteomics, 11(6), 663-73
Citation
Thevis, Mario; Thomas, Andreas; Schänzer, Wilhelm. (2014). Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.. Expert review of proteomics, 11(6), 663-73. https://doi.org/10.1586/14789450.2014.965159